News Bayer takes Alport syndrome drug into phase 2 Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome.
Patients Sponsored Why rare kidney diseases must be part of the CKD conversatio... A look at the benefits of genetic testing in diagnosis of rare kidney diseases, from HealthLumen.
News NHS trust rolls out digital health tool for kidney disease An NHS trust in England is starting a pilot study of a digital health platform that promises to improve the care of people with kidney disease.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
News AZ partners with Aptar on kidney disease-detecting AI AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD).
News When licensing deals go bad - Novo sues KBP Bio for $830m Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.
News Servier snaps up cancer biotech Day One in $2.5bn deal Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.